Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model.
While a time-kill methodology noted no appreciable improvement in bactericidal activity with the addition of azithromycin (AZM) to a ceftazidime (CAZ) regimen, data from the murine pneumonia model showed that the addition of AZM significantly improved survival compared to treatment with CAZ alone. These data suggest that AZM might be a useful adjunctive therapy in the management of pneumonia resulting from mucoid isolates of Pseudomonas aeruginosa.
Nicolau
D P
DP
Department of Pharmacy Research, Hartford Hospital, Hartford, Connecticut 06102, USA. dnicola@harthosp.org
Banevicius
M A
MA
Nightingale
C H
CH
Quintiliani
R
R
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017963:Azithromycin / Q000494:pharmacology / Q000627:therapeutic use*; D002442:Ceftazidime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D051379:Mice; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D016019:Survival Analysis; D013997:Time Factors; D014552:Urinary Tract Infections / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D017963:Azithromycin; D002442:Ceftazidime